These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

969 related items for PubMed ID: 26026669

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Predictive biomarkers in adult gliomas: the present and the future.
    Thomas L, Di Stefano AL, Ducray F.
    Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
    [Abstract] [Full Text] [Related]

  • 5. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
    Michotte A, Neyns B, Chaskis C, Sadones J, In 't Veld P.
    Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
    [Abstract] [Full Text] [Related]

  • 6. [Prognostic and predictive factors for gliomas in adults].
    Frenel JS, Botti M, Loussouarn D, Campone M.
    Bull Cancer; 2009 Apr; 96(4):357-67. PubMed ID: 19357011
    [Abstract] [Full Text] [Related]

  • 7. [OMICS and biomarkers of glial tumors].
    Idbaih A.
    Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
    [Abstract] [Full Text] [Related]

  • 8. Pathological classification of brain tumors.
    Pollo B.
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):103-11. PubMed ID: 22617234
    [Abstract] [Full Text] [Related]

  • 9. Glioma biology and molecular markers.
    Cohen AL, Colman H.
    Cancer Treat Res; 2015 Apr; 163():15-30. PubMed ID: 25468223
    [Abstract] [Full Text] [Related]

  • 10. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
    Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W.
    Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
    [Abstract] [Full Text] [Related]

  • 11. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF.
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [Abstract] [Full Text] [Related]

  • 12. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M.
    Clin Cancer Res; 2005 Feb 01; 11(3):1119-28. PubMed ID: 15709179
    [Abstract] [Full Text] [Related]

  • 13. [Multidisciplinar approach to the management of gliomas].
    Moura B, Migliorini D, Bourhis J, Daniel R, Levivier M, Hottinger AF.
    Rev Med Suisse; 2016 Apr 27; 12(516):821-5. PubMed ID: 27281939
    [Abstract] [Full Text] [Related]

  • 14. Molecular genetics of gliomas.
    Appin CL, Brat DJ.
    Cancer J; 2014 Apr 27; 20(1):66-72. PubMed ID: 24445767
    [Abstract] [Full Text] [Related]

  • 15. [Diagnosis and prognosis of gliomas--current prospects of molecular diagnostics].
    Haapasalo J, Hyartt A, Salmi M, Nordfors K, Lahtela SL, Kähkönen M, Helén P, Haapasalo H.
    Duodecim; 2014 Apr 27; 130(9):893-901. PubMed ID: 24881141
    [Abstract] [Full Text] [Related]

  • 16. Molecular predictors of outcome in low-grade glioma.
    Weiler M, Wick W.
    Curr Opin Neurol; 2012 Dec 27; 25(6):767-73. PubMed ID: 23160425
    [Abstract] [Full Text] [Related]

  • 17. Molecularly based management of gliomas in clinical practice.
    Rudà R, Pellerino A, Magistrello M, Franchino F, Pinessi L, Soffietti R.
    Neurol Sci; 2015 Sep 27; 36(9):1551-7. PubMed ID: 26194534
    [Abstract] [Full Text] [Related]

  • 18. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
    Taylor JW, Chi AS, Cahill DP.
    Oncology (Williston Park); 2013 Jun 27; 27(6):504-14. PubMed ID: 23909061
    [Abstract] [Full Text] [Related]

  • 19. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
    Neurology; 2013 Oct 22; 81(17):1515-22. PubMed ID: 24068788
    [Abstract] [Full Text] [Related]

  • 20. [Histological and molecular classification of gliomas].
    Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.
    Rev Neurol (Paris); 2008 Oct 22; 164(6-7):505-15. PubMed ID: 18565348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.